Rhone Ma Holdings Bhd
Rhone Ma Holdings Bhd is a pharmaceutical company that develops, manufactures, and distributes prescription and over-the-counter drugs, primarily in Malaysia and Southeast Asia.
Business. Rhone Ma Holdings Bhd (RHON.KL) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Malaysia and is primarily listed on the Bursa Malaysia stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
1Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Rhone Ma Holdings Berhad (RHON.KL) is currently undergoing its first formal analysis, meaning there is no prior historical basis for computing material changes or performance deltas. Consequently, no specific operational shifts, financial adjustments, or strategic pivots can be identified from the available data to drive a narrative of change. The company’s current profile indicates a lack of external market engagement metrics, with zero recorded officers, analysts, index memberships, or top holders in the dataset. This absence of tracked stakeholders suggests that the entity is either newly listed, thinly traded, or not yet integrated into standard financial monitoring frameworks. Cross-source signal analysis reveals minimal activity, with only a single dispatch recorded on July 16, 2026, amidst a broader period of zero daily dispatches from late June through mid-July 2026. The sentiment for this isolated event is undefined, and the overall volume of information flow remains negligible. Given the lack of material changes, watcher signals, or saga developments, the significance of Rhone Ma Holdings Berhad’s current status is defined by its informational vacuum. Investors and analysts lack the foundational data required to assess risk, valuation, or strategic direction, limiting any substantive financial commentary at this stage.
Signals & dispatch
Composite-score breakdown
Synthesis
Rhone Ma Holdings Bhd (RHON.KL) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Malaysia and is primarily listed on the Bursa Malaysia stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Rhone Ma Holdings Bhd maintains a conservative capital structure with a debt-to-equity ratio of 0.18, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 4.75, suggesting strong short-term liquidity. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints in the near term.
In terms of profitability, the company's return on equity (ROE) is 1.96%, and its return on assets (ROA) is 1.42%. These figures are below the industry median for ROE and ROA in the pharmaceutical sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.
The company's revenue is primarily concentrated in Malaysia and Southeast Asia, with no disclosed breakdown of segment or geographic revenue. This lack of diversification could expose the company to regional economic and regulatory risks, particularly in a sector that is highly sensitive to healthcare policy changes.
Looking ahead, the company's growth trajectory is expected to remain modest, with no significant revenue growth projected in the current or next fiscal year. Historical revenue trends show a stable but non-explosive growth pattern, which is consistent with the company's current market position and industry dynamics.
The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, which could impact its ability to fund operations or invest in growth opportunities without external financing.
Recent filings and transcripts do not indicate any major strategic shifts or significant events that would alter the company's current trajectory. The company appears to be maintaining a steady course, with no major new product launches or market expansions disclosed in the latest available documents.
Rhone Ma Holdings Berhad (RHON.KL) is currently undergoing its first formal analysis, meaning there is no prior historical basis for computing material changes or performance deltas. Consequently, no specific operational shifts, financial adjustments, or strategic pivots can be identified from the available data to drive a narrative of change. The company’s current profile indicates a lack of external market engagement metrics, with zero recorded officers, analysts, index memberships, or top holders in the dataset. This absence of tracked stakeholders suggests that the entity is either newly listed, thinly traded, or not yet integrated into standard financial monitoring frameworks. Cross-source signal analysis reveals minimal activity, with only a single dispatch recorded on July 16, 2026, amidst a broader period of zero daily dispatches from late June through mid-July 2026. The sentiment for this isolated event is undefined, and the overall volume of information flow remains negligible. Given the lack of material changes, watcher signals, or saga developments, the significance of Rhone Ma Holdings Berhad’s current status is defined by its informational vacuum. Investors and analysts lack the foundational data required to assess risk, valuation, or strategic direction, limiting any substantive financial commentary at this stage.
- Rhone Ma Holdings Bhd has a conservative capital structure with a low debt-to-equity ratio of 0.18.
- The company's ROE and ROA are below the industry median, indicating underperformance in capital efficiency and asset utilization.
- Revenue is concentrated in Malaysia and Southeast Asia, exposing the company to regional economic and regulatory risks.
- The company's growth trajectory is expected to remain modest, with no significant revenue growth projected in the near term.
- The company faces a medium liquidity risk due to a negative net cash position after subtracting total debt.
Bull / Bear case
Generated · model-assistedRevenue grew 32% year-over-year to MYR 223.7 million, demonstrating strong top-line expansion momentum.
Free cash flow surged 536% to MYR 12.2 million, reflecting exceptional cash generation capabilities.
Cash conversion ratio of 5.1 is best-in-class compared to the cohort median of 0.95.
Long-term debt decreased to MYR 20.6 million, improving the balance sheet strength relative to prior periods.
The company faces high credit risk, which could impair financial stability and increase borrowing costs.
Medium liquidity risk suggests potential challenges in meeting short-term obligations or trading constraints.
Net income growth of 25.7% lagged behind the 32% revenue growth, indicating margin compression pressures.
Return on assets of 1.42% remains low, suggesting limited efficiency in generating profits from total assets.
In focus — financials by report
Revenue MYR 211.4M, +4,2% YoY; Operating income +2,8% YoY.
- ▍Revenue MYR 211.4M, +4,2% YoY
- ▍Operating income +2,8% YoY
- ▍Net income +1,9% YoY
- ▍Free cash flow −0,5% YoY
- ▍Net margin 5.8%
Revenue MYR 202.9M, +2,4% YoY; Operating income −4,0% YoY.
- ▍Revenue MYR 202.9M, +2,4% YoY
- ▍Operating income −4,0% YoY
- ▍Net income −5,2% YoY
- ▍Free cash flow −15,9% YoY
- ▍Net margin 6.0%
Revenue MYR 198.2M, +16,9% YoY; Operating income +8,0% YoY.
- ▍Revenue MYR 198.2M, +16,9% YoY
- ▍Operating income +8,0% YoY
- ▍Net income +13,1% YoY
- ▍Free cash flow +516,8% YoY
- ▍Net margin 6.4%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Rhone Ma Holdings Bhd Market data — financials · 2026-05-29